Prophylaxis of mould infections
E Moreno-García, M Chumbita, P Puerta-Alcalde
1Carolina Garcia-Vidal, Infectious Diseases Department, Hospital Clínic de Barcelona-IDIBAPS, Universitat de Barcelona, Barcelona, Spain. carolgv75@hotmail.com.
Abstract:
Invasive fungal infection continues to be an important cause of morbidity and mortality in haematological patients. Antifungal prophylaxis in these patients has remarkably increased survival since its introduction. In recent years, new antifungals have been on the rise, being more effective and having less toxicity than previous ones. Nonetheless, the number of patients at risk of fungal infection has also been increasing due to the continuous appearance of new immunosuppressive treatments. As a result of such, we face a changing situation that requires constant updating.
Insights
Antifungal prophylaxis significantly improves survival in patients with hematological conditions. However, evolving immunosuppressive treatments necessitate continuous updates in antifungal strategies to combat rising invasive fungal infection risks.
Area of Science:
- Hematology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFIs) are a major cause of death in hematological patients.
- Antifungal prophylaxis has dramatically improved survival rates in this vulnerable population.
- Newer antifungals offer improved efficacy and reduced toxicity compared to older agents.
Purpose of the Study:
- To review the current landscape of antifungal prophylaxis in hematological patients.
- To highlight the challenges posed by emerging immunosuppressive therapies.
- To emphasize the need for ongoing adaptation of antifungal strategies.
Main Methods:
- Literature review of recent studies on antifungal prophylaxis.
- Analysis of trends in immunosuppressive treatments and IFI incidence.
- Synthesis of data on newer antifungal agents.
Main Results:
- Antifungal prophylaxis remains critical for survival in hematological patients.
- Increasing use of novel immunosuppressants expands the population at risk for IFIs.
- Development of more effective and safer antifungal drugs is ongoing.
Conclusions:
- Despite advances, invasive fungal infections remain a significant threat in hematology.
- The dynamic nature of immunosuppressive therapies requires continuous reassessment of prophylaxis protocols.
- Regular updates in antifungal strategies are essential to manage evolving risks and improve patient outcomes.
Related Concept Videos
Infection
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
05:32Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
09:32Oral Bacterial Infection and Shedding in Drosophila melanogaster
Stages of Infection
07:59Bioluminescence Imaging to Detect Late Stage Infection of African Trypanosomiasis
12:30Use of Galleria mellonella as a Model Organism to Study Legionella pneumophila Infection


